Pulmonary diffusing capacity for carbon monoxide (DL) is a valuable pulmonary function test to evaluate the gas exchange capacity of the lungs. Generally, DL values are significantly lower in patients with chronic obstructive pulmonary disease (COPD), particularly in those with a predominantly emphysema phenotype. However, it is extremely rare that DL values cannot be obtained for reasons other than technical errors. Herein, we report two patients with COPD in whom DL values were undetectable without prolonging the breath-holding time for the test. We discuss possible mechanisms for these peculiar findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.resinv.2020.08.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Minimising inhaled corticosteroids for COPD.
Afr J Prim Health Care Fam Med
December 2024
Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.
This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms.
View Article and Find Full Text PDFSpirometric pattern and cardiovascular risk: a prospective study of 0.3 million Chinese never-smokers.
Lancet Reg Health West Pac
January 2025
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
Background: Existing studies have not provided robust evidence about the CVD risk of non-smoking patients with restrictive spirometric pattern (RSP) or airflow obstruction (AFO), and how the risk is modified by body shape. We aimed to bridge the gap.
Methods: We used never-smokers' data from the China Kadoorie Biobank (CKB) and performed Cox models by sex (278,953 females and 50,845 males).
Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1.
MedComm (2020)
February 2025
Chronic kidney disease (CKD) is a disease that affects more than 850 million people. Acute kidney injury (AKI) is a common cause of CKD, and blocking the AKI-CKD transition shows promising therapeutic potential. Herein, we found that butyrolactone I (BLI), a natural product, exerts significant nephroprotective effects, including maintenance of kidney function, inhibition of inflammatory response, and prevention of fibrosis, in both folic acid- and ureteral obstruction-induced AKI-CKD transition mouse models.
View Article and Find Full Text PDFComprehensive bioinformatics analysis identifies metabolic and immune-related diagnostic biomarkers shared between diabetes and COPD using multi-omics and machine learning.
Front Endocrinol (Lausanne)
January 2025
Department of Integrated Pulmonology, Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, Xinjiang, China.
Background: Diabetes and chronic obstructive pulmonary disease (COPD) are prominent global health challenges, each imposing significant burdens on affected individuals, healthcare systems, and society. However, the specific molecular mechanisms supporting their interrelationship have not been fully defined.
Methods: We identified the differentially expressed genes (DEGs) of COPD and diabetes from multi-center patient cohorts, respectively.
Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis.
Front Med (Lausanne)
January 2025
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Objective: The current study was designed with the aim of conducting a systematic review and meta-analysis to determine the circulating levels of visfatin in patients with chronic obstructive pulmonary disease (COPD) compared to healthy individuals.
Methods: Until March 2024, we searched the Web of Science, PubMed/Medline, and Scopus databases. The analysis included case-control studies assessing the association between circulating visfatin and COPD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!